Peptides Weekly

Patrick · Nerra Network
  • 0.0 (0)
  • Medicine
  • Updated Weekly

What peptides are, what the evidence actually shows, and what is approved, investigational or unregulated. Every Thursday: the week in peptide science and regulation, and one peptide explained properly — mechanism, studies, status, risks. Education only; never dosing, sourcing or protocols, and never medical advice. AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production.

Episodes

  1. 1d ago

    Ep 5: Three to four extra rare vision-loss cases per ten thousand showed up in an observational…

    Peptides Weekly Three to four extra rare vision-loss cases per ten thousand showed up in an observational GLP-1 study. What You Need to Know: Three to four extra rare vision-loss cases per ten thousand showed up in an observational GLP-1 study. The link was seen in adults with type 2 diabetes and does not prove the drugs injured the optic nerve. ... Sources: ua.news · sciencedaily.com · biospace.com · medicaldaily.com · bipc.com · komu.com AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. If this episode was useful, a rating or a short review on Apple Podcasts or Spotify is how the next listener finds the show — and following it in your app means the next episode is there when you are. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

  2. Oct 8

    Ep 4: Unapproved peptides could reach temporary sale while treatment claims are still not fully…

    Peptides Weekly Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. What You Need to Know: Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. Political Wire, quoting The Washington Post, describes a drafting process for previously restricted peptides, not a completed approval and not a patient trial. ... Sources: washingtonpost.com · stocktwits.com · ascopost.com · amp.sacbee.com · foodnavigator.com AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. If this episode was useful, a rating or a short review on Apple Podcasts or Spotify is how the next listener finds the show — and following it in your app means the next episode is there when you are. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

  3. Oct 1

    Ep 3: Nail detachment was over four times more common in people using GLP-1 drugs.

    Peptides Weekly Nail detachment was over four times more common in people using GLP-1 drugs. What You Need to Know: A controlled study found nail detachment more than four times as often among people using GLP-1 drugs. The same week brought a muscle-loss trial beside semaglutide, a randomized look at how semaglutide meets the kidney, and two reminders that a population trend and a protein-design paper are not treatment results. ... Sources: medicalxpress.com · reuters.com · nature.com · t.co AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

  4. Sep 24

    Ep 2: Nearly one in six children taking GLP-1 drugs show nutritional deficiencies in a new study.

    Peptides Weekly Nearly one in six children taking GLP-1 drugs show nutritional deficiencies in a new study. What You Need to Know: A retrospective analysis found nutritional deficiencies in almost 17 percent of children prescribed GLP-1 receptor agonists for weight loss or diabetes. The finding comes from claims data and highlights a measurable gap in monitoring for younger patients. ... Sources: sciencedaily.com · yaledailynews.com · euractiv.com · velo.outsideonline.com · sciencedirect.com · europepmc.org AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

  5. Sep 23

    Ep 1: Phase 3 results for an investigational amylin peptide medicine in diabetes and obesity were…

    Peptides Weekly Phase 3 results for an investigational amylin peptide medicine in diabetes and obesity were released this week. What You Need to Know: Novo Nordisk reported new phase 3 data on an amylin-based candidate. A pair of randomized trials found oral semaglutide did not slow progression in mild Alzheimer’s disease. ... AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

  • 5 Episodes

About

What peptides are, what the evidence actually shows, and what is approved, investigational or unregulated. Every Thursday: the week in peptide science and regulation, and one peptide explained properly — mechanism, studies, status, risks. Education only; never dosing, sourcing or protocols, and never medical advice. AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production.

Information

  • Creator
    Patrick · Nerra Network
  • Years Active
    2026
  • Episodes
    5
  • Rating
    Clean
  • Copyright
    © Copyright 2026
  • Show Website
    Peptides Weekly